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Summary Zinc phthalocyanine (ZnPc) is a second-generation photosensitiser for the photodynamic therapy
(PDT) of cancer. Unsubstituted ZnPc is, however, highly insoluble in most common solvents, and for clinical
applications the material needs to be incorporated in liposomes. We report a simple, alternative procedure to
formulate ZnPc through non-covalent binding to bovine serum albumin (BSA). Intravenous administration of
ZnPc-BSA preparations, at a molar ratio of 11: 1 and at a ZnPc dose equivalent to 0.5 mol kg- , to tumour-
bearing mice followed 24 h later by PDT was shown to provide tumour control in two different models, the
EMT-6 tumour in Balb/c mice and the human colon T380 carcinoma in nude mice. Analysis of serum fractions
from treated animals showed that ZnPc readily redistributes over the serum high-density lipoprotein (HDL)
fraction. We also demonstrated the absence of hepatic toxicity of the ZnPc-BSA preparation by monitoring
the hepatic cytochrome P450 activiy in treated animals and the viability of human cultured hepatocytes.
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Fluorescence properties and preferential retention of dyes in
malignant tissues allow the clinical diagnosis of various
human neoplasms (Dougherty et al., 1978). If the photo-
excited dyes are capable of in situ energy or electron transfer,
they can also be used as sensitisers for the photodynamic
therapy (PDT) of tumours. The most widely studied dye for
PDT, Photofrin (Pll), consists of a mixture of haematopor-
phyrin derivatives, and this preparation has been approved
for clinical use (Levy, 1995). However, the relatively low
absorbance above 600 nm (at which tissues provide optimal
transparency) and some pharmacodynamic drawbacks have
led to the development of new dyes for PDT (Morgan et al.,
1988; van Lier, 1988). Among them, the phthalocyanines (Pc)
have advantageous photophysical properties and numerous
studies have been conducted to demonstrate the potential of
these molecules for PDT (van Lier, 1990; Rosenthal, 1991).
Low solubility of the non-substituted metallo Pcs in
biological fluids prompted chemical modifications to
decrease their hydrophobicity (Ali et al., 1988; Chan et al.,
1990). Albeit such changes may result in a decrease in their in
vivo photoactivity, mono- and di-sulphonated derivatives are
capable of cell membrane penetration resulting in increased
potency to inflict direct cell kill during PDT (Brasseur et al.,
1988; Paquette and van Lier, 1992; Margaron et al., 1996).
Among the non-substituted Pcs, the zinc complex (ZnPc) has
been studied in great detail (Ginevra et al., 1990; Reddi et al.,
1990). Owing to its extreme insolubility in most common
solvents, ZnPc needs to be incorporated in liposomes, and a
proprietary formulation has been proposed for clinical use
(Schieweck et al., 1994).
In this study, we evaluate the PDT potential of the readily
available, unsubstituted ZnPc solubilised with bovine serum
albumin (BSA) and compare its PDT potency with that of
two sulphonated ZnPcS derivatives. Photodynamic properties
of the latter dyes have previously been reported in mice
bearing the sarcoma type EMT-6 mouse mammary tumour
(Paquette and van Lier, 1992), and we used the same model
in the present study. In addition, we evaluated tumour
control by ZnPc -BSA-PDT in the human colonic
carcinoma T380 implanted in nude mice. The dark toxicity
and possible effects of this preparation on mouse liver-
detoxifying enzymes, such as cytochromes P450 and
glutathione transferase, is evaluaied. Behaviour of human
cultured hepatocytes exposed to the ZnPc-BSA preparation
is also reported.
Materials and methods
Animals and tumour models
Mice were maintained and handled in accordance with the
recommendations of a local animal care committee. The
animals were allowed free access to water and food
throughout the course of the experiment. The EMT6 mouse
mammary tumour cell line was obtained from Dr C-W Lin
(Massachusetts General Hospital, Boston) and maintained
according to an established protocol (Rockwell et al., 1972).
Tumours were implanted in Balb/c mice on each hind thigh
by intradermal injection of 2 x 105 EMT6 cells suspended in
50 !l of Waymouth growth medium. The human colon
carcinoma T380 (Martin and Halpern, 1984) was serially
transplanted subcutaneously into the right flank of 7- to 9-
week-old female Swiss nu/nu mice (Iffra Credo, l'Arbresle,
France). After 2 weeks, the mice were randomised to different
treatment and control groups. Both models were used for
PDT when tumours reached at least 8 -10 mm in diameter.
The tumour volume on nude mice was evaluated by
measuring the tumour diameters (three dimensions) and
applying the formula volume = rI x r2 x r3 x 47r/3 (r=radius).
Zinc phthalocyanine-albumin preparation
Zinc phthalocyanine (Aldrich 34,116-9) was prepared as a
saturated (1.7 mM) dimethylformamide (DMF) solution. This
solution was added dropwise to a 1 mg ml-' bovine serum
albumin (BSA) preparation in phosphate buffer (50 mM,
pH 7.4) under gentle stirring. The final DMF concentration
did not exceed 5%. Solid ammonium sulphate (0.625 g ml-',
85% saturation) was added to the mixture, which was then
stirred at 4°C for 10 min and centrifuged at 10 000 g for
10 min. The clear supernatant was discarded and the
coloured pellet was redissolved in phosphate buffer. This
procedure was repeated until the ZnPc-BSA ratio remained
stable. The final preparation was dialysed overnight against
PBS to remove the excess of ammonium sulphate and used
immediately or lyophylised. The lyophylised ZnPc-BSA
preparation can be reconstituted in PBS and this solution
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was shown to be stable for several weeks at 4°C. ZnPc-BSA
ratios were measured after a 100-fold dilution in DMF
(ZnPc: .max = 678 nm, £ = 2.45x 105 M-' cm-1).
Phototherapy
Either Balb/c or nude tumour-bearing mice were given an
intravenous injection of the dye preparation via the lateral
tail vein (maximal volume 0.2 ml). Phototherapy was applied
24 h after dye administration. EMT-6 or T380 tumour-
bearing mice were anaesthetised with an intraperitoneal
injection of tribromoethanol (230 mg kg-' in PBS, 10%
ethanol). The tumours were centred under the red spot
(diameter 1-1.5 mm) of a light source consisting of a
focalised Xenon Cermax LX-300 F (ILC Technology,
Sunnyvale, CA, USA) fitted with a 10 cm long water cell to
remove infrared radiation and a 676 nm interference filter
(bandpass+ 10 nm) (Optometrics, Leeds, UK). Illumination
times were adjusted to deliver the desired light dose, as
measured with a Photon Power Meter (Spectra-Physics
Model 404). No hyperthermia was observed under these
conditions. Response of the EMT-6 tumour was assessed by
observation of the tumour necrosis followed by the absence
of palpable tumour within 3 weeks after the treatment. In the
case of the T380 tumours, the measurement of the tumour
volume over a 2 month period was used to assess tumour
response.
Fractionation of serum proteins
Balb/c mice blood was collected 24 h after injection of the
ZnPc-BSA (11: 1) preparation (2 ,mol of ZnPc per kg) and
the serum was separated after a short centrifugation. The
various protein components were then separated on a
potassium bromide density gradient in a Beckman VTi 65-2
rotor operating at 60 000 g for 2 h (Chung et al., 1986). The
potassium bromide concentration was adjusted in order to
obtain a final gradient density between 1.06 and 1.22.
Fractions were then recovered from the top of the tube.
The density of each fraction was monitored using a
thermostated PAAR DMA 40 Digital Density Meter (An-
ton Parr, Graz, Austria) and ZnPc fluorescence was measured
on an Aminco-Bowman spectrofluorimeter (ex =646 nm,
,em=680 nm, 5 nm bandpass) after calibration of the
apparatus with successive dilutions of ZnPc in mouse
serum. The nature of the proteins in each fraction was
verified by polyacrylamide gel electrophoresis. The amont of
total protein was estimated using the BCA method (Pierce,
Rockford, MA) and bromocresol green was used to quantify
albumin specifically in each fraction (Doumas et al., 1971).
Liver detoxification
Balb/c mice were injected intraperitoneally with a ZnPc BSA
(11: 1) preparation (ZnPc dose of 2 pmol kg-') over a 4 day
period. On day 5, the animals were sacrificed, livers removed
and the microsomal and cytosolic fraction prepared.
Progesterone is a good substrate for hepatic cytochrome P-
450, and the pattern of metabolites is indicative of the
concentration and nature of the various hydroxylases.
Microsomal metabolic profiles of progesterone were pre-
pared as previously described (Larroque et al., 1989).
Enzymatic assays and human hepatocyte handling
Microsomes and cytosol from treated or untreated mice were
prepared by successive centrifugation as previously described
(Lu and Levin, 1972). The microsomal cytochrome P-450
activity was tested using progesterone as substrate, and the
metabolite composition was analysed after thin-layer
chromatography and liquid scintillation counting (Larroque
et al., 1989). Total glutathione-S-transferase activity was
assayed on the cytosolic fraction with 1-chloro-2,4-dinitro-
benzene as substrate (Habig et al., 1974). Human hepatocytes
were prepared from hepatic lobectomies (as approved by the
French National Ethics Committee), and cultured in a serum-
free medium as previously described (Diaz et al., 1990). The
overall metabolic integrity of hepatocytes in culture was
assessed by measuring the rate of de novo protein synthesis in
24 h (Pichard et al., 1992), after the cells have been incubated
in the dark for 6 days with various concentrations of the
ZnPc-BSA preparation. All of the chemicals used in this
study were of the highest purity commercially available.
Results
Figure 1 shows the electronic spectrum of a ZnPc-BSA
preparation. Superimposed is the transmission of the red light
source. The relatively short bandpass from the 676 nm
interference filter limits unwanted interactions with endogen-
ous porphyrins. For a typical ZnPc-BSA preparation the
dye content was 11 mol of ZnPc per mol of BSA. A lower
ratio diminished the PDT potency, whereas a higher loading
ratio did not improve tumour response.
Photodynamic therapy
The PDT efficacy of ZnPc-BSA was first compared with the
known activities of the mono- and tetra-sulphonated ZnPcS1
and ZnPcS4 in Balb/c mice bearing EMT-6 mammary
tumours. Tumour responses, after irradiation with red light
(. = 676 nm, 400 J cm-2, 100 mW cm-2) 24 h after injection
of the various photosensitiser preparations, are summarised
in Table I. These data show that tumour control can be
achieved under these conditions with ZnPc-BSA at a ZnPc
dose level of 0.5 pmol kg-'. These results demonstrate that
absorption of commercially available ZnPc to serum albumin
provide a dye preparation with similar PDT efficacy to the
synthetic, water-soluble ZnPcS, preparation. These data
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Figure 1 Electronic absorption spectrum of a ZnPc-BSA (11: 1)
preparation ( ) and transmission of the interference filter used
for the phototherapy (-
- -).
Table I PDT of EMT6 tumours grafted on Balb/c mice
Tumour evolutionb after
Dose Animals
Dye (limol ZnPc included in 1 3
preparation per kg) the series 24 h 96 h wveek w,eeks
ZnPc- BSA 0.1 6 B C D A
ZnPc-BSA 0.5 18 B C E E
ZnPc-BSA 1.0 12 B C E E
Free-ZnPcS1 0.5 12 B C E E
Free-ZnPcS4 1.0 6 A A A A
aZnPc-BSA (ratio 11: 1); SI, monosulphonate; S4, tetrasulphonate.
bA, no effect; B, black oedema; C, flat necrotic area; D, tumour
regrowth; E, no palpable tumour.
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prompted US to extenid our evaluLation to a humani tumour
model. The humclan colon carcinomiia T380 grafted oni nude
mllice was selected, since this typc of cancer is clinically readily
accessible lor PDT, and this model has becn used in miany
radiotherapy and radioim"munotherapy studies (Martin and
Halpern, 1984: Buchegger eit fl., 1990). The palrticullar
physiology otf nude mice (especially transparency of the
skin) obliged LIS to ULse a lower light dose to avoid liver
dysfunctioni alfter illumination. A maximum light dose of
20() J cm ' with a fluenice rate of 30 mW cm a' was selected
for these experimnenits; the aidministe-ed ZnPc dose being
arbitrarily adjusted to 2 Iimol kg '. Micc that received the
ZnPc BSA preparation aind light were comppared with
untreated imlice as well as with mice that received dye or
light only. In all mice that received the complete PDT
treatment (dye and illumination), tumour dcamage was clearly
visible within 8 h after irradiation leacding to a black oedema
and blood leakage airound the tuLmour, which became less
adherent to the muscle and the skin of the animal. In the
following 4 days, the oedema disappeared leading instead to
a necrotic area tfor the next 5 7 days. Subsequently. the
tre'ated animials werc apparently tumoul free up to 25 dcays
after the PDT. None of these responses were observed in the
control animnals, which showcd an cxponential tumllour
growth to an average tumour size of 500 mg on day 24
after inoculaltion (Figure 2). In the tre'ated group, the 500 mg
tuIllour sizc was observed only on day 49 after the tumour
implant. The regrowth of the tumour in the treated mice that
werc apparently tumour free could bc attributed to cells
which did not receive the complete light dose, i.e. deeper-
seated cells or cells outside the light spot.
Serm(11.5 tdivriition *,/f Pc
Figurc 3 depicts the ZnPc fluor-cscence, the albumin contenit
and the density of each 500 jil fraction collected 'after
centrifug,ation of serum from dye-treated animals in a
potassiumll bromide density gradient. The albuminl-rich
f1raction is at the bottom of the tube, whereas the ZnPc
fluorescence is associcated with al protein fraction of a density
betweenl 1 .09 and I 1 3. This density range is compatible with
that of high-density lipoproteins (HDLs) (Gotto et al., 1986).
No fluorescence was detected in lighter or heavier fractions
revecaling that ZnPc did not associ'ate with lipoprotcins of low
density (chylomicrons, LDL or IDL) aind that complete
transfer from albumin to HDL hald occurred. The identity of
the protein fraction carrying ZnPc as HDL was confirmed by
a polyacrylamide gcl electrophoresis (data not shown), which
permits the detectioni ot 18 000 to 22 000 Da fragmenits
comparable in moleculkar weight to ApoA-II or ApoD from
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Figure 2 EVOIlutioI of the volume (imCeaII Iand standard deviation)
of T38() experimental tumours grafted on nude mice receiving on
day It) after the graft: no treatmeit (0). light Ilone (A). ZnPc
BSA (2 Xtmol ZnPc per kg) alone (0-1), or ZnPc BSA (21imol
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Figure 3 Fractionation of' serumi proteinis by centrlifugation 241h
after the mice were injected wsith a preparation of ZnPc BSA.
The fractionis wiere collected from the top to thc bottom of' the
centrifuge tube. The density (- ), the albumin concentration
and the phthalocyanine fluorescence ( ) were 'assayed in each
fraction.
high-density lipoproteinis (Gotto ci tl.., 1986). This ZnPc
distributioni profile contrasts with the pattern observed by
Ginevra ct al. (1990) using ZnPc incorporated in a liposomal
vehicle. It is evident that the dye formulation greatly
influences serum distribution of the ZnPc. In view of these
results, we 'also measured PDT response after ZnPc
administration as aImouse HDL ZnPc complex and found
th'at tumour response was in all respects similar to that
observed with the ZnPc BSA preparation (data not shown).
EJ/ cdts ot /ZnPc BSA on li1er dIeto.vxifilng v cmstems
Progesteronie metabolic profiles aind cytochrome P-450
content of hepatic Imicrosomes from treated and untreated
Ianimials were compared. No significant difference could be
detected, either on the cytochrome P-450 content or on the
nature or amount of progesterone metabolites produced.
Similalrly, no effect was detectable on the glutathione
transferase activity in the hepatic cytosolic fractions derived
from the valrious animals. An enzyme activity of 35 +4 nmol
of chloro 2,6-dinitrobcnzene conjugated per mrin and per mg
of cytosolic proteins was observed for all cytosols tested, both
Irom treatcd or untreated mice.
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Figure 4 Eflect of vlarious concentrations of ZnPc BSA
preparation on human cultured hepatocytes. The daIrk toxicity
is meaisured as the influeiice of the dye preparation on the
incorpor.ation of tritiaIted leucine in de ntovo synthesised proteins
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Effect of ZnPc-BSA on human cultured hepatocytes
As stated, phthalocyanines are easily trapped by the liver.
The capacity of human hepatocytes to synthesise proteins
after 6 days of incubation with various concentrations of
ZnPc-BSA is seen in Figure 4. The lowest concentration
used (e.g. 6 iM of BSA-bound ZnPc) corresponds to the
maximum ZnPc concentration in the serum of mice that
received ZnPc-BSA equivalent to a ZnPc dose of
1 ,umol kg-'. As can be seen from Figure 4, toxicity only
becomes evident at ZnPc concentrations exceeding 30 gM.
This observation is in line with our other findings and
confirms the relatively low toxicity of the ZnPc-BSA
preparation.
Discussion
The delivery of hydrophobic dyes to tumour cells has been
proposed to proceed via a transport by lipoproteins (Ginevra
et al., 1990). The present study demonstrates that the BSA-
delivered ZnPc readily redistributes from the carrier protein
to the serum lipoproteins, particularly the HDL fraction.
Thus, the in vivo PDT effect following ZnPc-BSA
administration is likely to involve the same mechanism as
that observed with similar dyes delivered via liposomal
preparations (Reddi et al., 1990). Compared with the latter,
ZnPc loading on albumin is a relatively simple procedure
(Schieweck et al., 1994). To avoid antigenecity problems, it is
evident that the same procedure can be used with human
albumin preparations.
The PDT efficacy of the ZnPc-BSA is similar to that of
the monosulphonated ZnPcS,. However, the latter prepara-
tion requires extensive chromatographic purification and
consists of a mixture of positional isomers (Ali et al.,
1988). Accordingly, the ZnPc-albumin formulation promises
to be more suitable for scaling up to the quantities required
in a clinical setting.
The liver is the principal site for the oxidation and
detoxification of foreign materials, and the lipophilic
phthalocyanines are known to be largely retained by the
liver. Previous in vitro studies on isolated liver microsomes
demonstrated the deleterious effect of phthalocyanine on
these structures (Agarwal et al., 1992). To mimic more closely
the photodynamic protocol, we studied the in vivo effect of
ZnPc-BSA on some essential liver functions. Finally, we
showed for the first time the lack of hepatic dark toxicity of
ZnPc, even at relative high dye concentrations. However, the
apparent accumulation of the dye in the liver remains a
problem, necessitating the use of lower light doses in our
nude mice model. Although the BSA vehicle allowed the
biodistribution of the dye throughout the whole animal,
increased tumour selectivity would obviously be desirable.
Covalent coupling of other dyes (fluorescein, indocyanin) to a
monoclonal antibody directed against tumour cells in nude
mice bearing colon or squamous cell carcinomas has been
demonstrated (Folli et al., 1992, 1994; Pelegrin et al., 1991),
and a similar approach for ZnPc targeting may further
enhance tumour specificity.
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